Stevanato Group S.p.A. STVN
- Market cap
- $5.8B
- P/E
- 37.7×
Follow STVN
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | 16.61 | 13.36 | 17.31 | 16.56 | 17.81 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | 29.18 | 23.30 | 36.30 | 34.73 | 28.00 |
High Price
|
|||
| — | — | — | — | 4,344 | 4,652 | 5,260 | 5,635 | 5,521 | 6,010 |
Employees
|
|||
| — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | 601 | 756 | 998 | 1,036 | 1,175 | 1,195 | 1,342 |
Revenue
|
|||
| — | — | — | 24.29% | 29.33% | 31.45% | 32.51% | 31.32% | 27.38% | 28.99% |
Gross Margin
|
|||
| — | — | — | 62 | 110 | 196 | 198 | 205 | 173 | 214 |
EBT
|
|||
| — | — | — | 10.32% | 14.54% | 19.63% | 19.08% | 17.46% | 14.52% | 15.94% |
EBT Margin
|
|||
| — | 0 | — | 44 | 110 | 196 | 198 | 205 | 173 | 214 |
Net Income
|
|||
| — | — | — | 52 | 62 | 67 | 68 | 85 | 87 | 100 |
Depreciation
|
|||
| — | — | — | 2.27 | 3.14 | 3.95 | 3.92 | 4.43 | 4.41 | 4.92 |
Revenue/Sh
|
|||
| — | — | — | 0.17 | 0.37 | 0.63 | 0.57 | 0.60 | 0.47 | 0.58 |
Earnings/Sh
|
|||
| — | — | — | 0.18 | 0.74 | 0.62 | 0.41 | 0.43 | 0.62 | 1.19 |
Cash Flow/Sh
|
|||
| — | — | — | 0.00 | (0.46) | (0.52) | (0.97) | (1.80) | (1.24) | (1.13) |
Capex/Sh
|
|||
| — | — | — | 0.18 | 0.28 | 0.10 | (0.56) | (1.37) | (0.62) | 0.05 |
Free CF/Sh
|
|||
| — | — | — | 1.12 | 1.47 | 3.94 | 3.96 | 4.63 | 5.60 | 6.16 |
Book Value/Sh
|
|||
| — | — | — | 265 | 241 | 253 | 265 | 265 | 271 | 273 |
Shares
|
|||
| — | — | — | 38.33 | 38.33 | 35.45 | 31.23 | 45.03 | 45.40 | 34.69 |
PE Ratio
|
|||
| — | — | — | 5.64 | 5.64 | 5.68 | 4.47 | 5.99 | 4.95 | 4.09 |
PS Ratio
|
|||
| — | — | — | 10.31 | 10.31 | 5.70 | 4.41 | 5.74 | 3.89 | 3.27 |
PB Ratio
|
|||
| — | — | — | 5.95 | 5.95 | 5.46 | 4.42 | 6.29 | 5.25 | 4.37 |
EV/Sales
|
|||
| — | — | — | 16.05 | 16.05 | 215.94 | (31.15) | (20.32) | (37.47) | 401.67 |
EV/FCF
|
|||
| — | — | — | 48 | 178 | 158 | 109 | 114 | 169 | 324 |
Op' Cash Flow
|
|||
| — | — | — | (83) | (110) | (133) | (256) | (478) | (336) | (309) |
Capex
|
|||
| — | — | — | 48 | 68 | 25 | (147) | (364) | (167) | 15 |
FCF
|
|||
| — | — | — | 210 | 202 | 624 | 404 | 311 | 436 | 461 |
Working Cap'
|
|||
| — | — | — | 433 | 429 | 294 | 231 | 432 | 470 | 533 |
Total Debt
|
|||
| — | — | — | 291 | 249 | (225) | (45) | 352 | 363 | 373 |
Net Debt
|
|||
| — | — | — | 298 | 354 | 996 | 1,049 | 1,226 | 1,520 | 1,682 |
Sh' Equity
|
|||
| — | — | — | 8.89% | 8.56% | 11.41% | 8.78% | 7.90% | 5.35% | 5.86% |
ROA
|
|||
| — | — | — | 0.00% | 12.20% | 15.55% | 12.62% | 8.61% | 5.79% | 6.84% |
ROIC
|
|||
| — | — | — | 12.98% | 27.50% | 23.54% | 14.72% | 13.86% | 9.28% | 9.88% |
ROE
|
|||
Stevanato Group S.p.A. peers in Medical Instruments & Supplies
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| BLCO Bausch + Lomb Corporation | $6.0B | 0.0× | Compare |
| MMSI Merit Medical Systems, Inc. | $5.2B | 35.7× | Compare |
| TFX Teleflex Incorporated | $5.1B | 0.0× | Compare |
| ATR AptarGroup, Inc. | $7.8B | 22.1× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| ICUI ICU Medical, Inc. | $4.2B | 137× | Compare |
| NVST Envista Holdings Corporation | $3.9B | 40.6× | Compare |
| PLSE Pulse Biosciences, Inc | $3.8B | 0.0× | Compare |
| ALGN Align Technology, Inc. | $10.4B | 25.5× | Compare |
Stevanato Group S.p.A. (STVN) key facts
- Stevanato Group S.p.A. (STVN) is a Medical Instruments & Supplies company in the Healthcare sector, listed on the New York Stock Exchange.
- Stevanato Group S.p.A.’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 12.3% from fiscal 2024.
- Net income was $214.0 million, or $0.58 per share (basic), a net margin of 11.8%.
- As of September 25, 2026, STVN traded at $21.13, a market capitalization of $5.8 billion.
- At that price the stock trades at 37.7× trailing-twelve-month earnings and 4.0× sales.
- Stevanato Group S.p.A. pays an annual dividend of $0.06 per share, a yield of 0.07%, with a payout ratio of 9.64%.
- Return on equity was 9.88% and debt-to-equity 0.29.
Stevanato Group S.p.A. (STVN) Latest News
4 Sep
Stevanato Group divests a subsidiary to boost margins and support future growth initiatives. Divestiture of a subsidiary represents a major strategic move likely to alter margins and company trajectory.
1 Sep
Riverwater views the market reaction to Stevanato Group (STVN) as an overreaction following oral GLP-1 drug launches. Oral GLP-1 launches carry potential to shift demand away from injectable formats but Riverwater signals the price move overstates any lasting effect on Stevanato.
10 Aug
Stevanato Group trimmed guidance while securing approvals for new GLP-1 pens, triggering investor reactions to the mixed signals. Trimmed guidance introduces downside risk to near-term results while GLP-1 pen approvals create material new revenue potential.
Stevanato Group (STVN) may be 16% undervalued following its earnings report and updated guidance. Earnings and guidance updates can moderately shift investor views and near-term stock performance for STVN.
9 Aug
Stevanato Group Q2 earnings call covered financial results, revenue trends, and operational outlook. Quarterly earnings updates supply performance data that can move near-term sentiment without shifting long-term strategy.
4 Aug
Stevanato Group reports biologics surge and Alina progress in Q2 2026 earnings call, driving revenue growth and strengthening market position in pharma packaging and delivery systems. Biologics surge and Alina progress represent major strategic growth drivers that can significantly boost revenue and competitive positioning.
Stevanato Group S.p.A. (STVN) Q2 2026 earnings call transcript released. Quarterly earnings call delivers updates on performance and outlook with moderate influence on valuation and sentiment.
Stevanato Group S.p.A. held its Q2 2026 earnings call covering financial results, operational updates and forward outlook for the company. Earnings call delivers financial metrics and guidance that can shift near-term sentiment but rarely alters long-term trajectory alone.
Stevanato Group (STVN) reported Q2 earnings that exceeded estimates. Quarterly earnings beat can moderately affect near-term stock price and sentiment.
Stevanato Group S.p.A. achieved 8% revenue growth in the second quarter of fiscal 2026. 8% quarterly revenue growth signals steady performance without major strategic or competitive shifts.
30 Jul
Stevanato Group's Alina pen injector has been incorporated into liraglutide combination products that received marketing authorizations in multiple European countries. Marketing authorizations expand European market access and revenue potential for Alina pen injectors.
8 Jun
Stevanato Group introduces Deora pen injector for subcutaneous delivery in diabetes and weight management. New product launch expands portfolio in high-growth diabetes and obesity markets.
9 May
Stevanato Group S.p.A. (STVN) beat analyst earnings forecasts, prompting analysts to update their models. Beating earnings forecasts drives analyst upgrades and boosts STVN's market performance and investor sentiment.
8 May
Stevanato Group (STVN) released Q1 2026 earnings call transcript detailing quarterly financial results, operational updates, and forward guidance. Q1 2026 earnings transcript discloses financial performance and strategic outlook significantly impacting STVN's market trajectory and investor sentiment.
Stevanato Group S.p.A. released Q1 2026 earnings call summary highlighting financial results, operational updates, and future outlook. Q1 2026 earnings disclosure affects financial performance and investor sentiment but is balanced by market factors.
7 May
Stevanato Group (STVN) Q1 earnings and revenues beat analyst estimates. Beating Q1 earnings estimates signals strong financial performance and enhances investor sentiment.
Stevanato Group S.p.A. (STVN) reported 7% revenue growth, or 10% at constant currency, for the first quarter of fiscal 2026. Q1 revenue growth of 7% (10% constant currency) signals solid financial performance with moderate positive influence on market sentiment.
30 Apr
Stevanato Group (STVN) reports earnings next week, with Wall Street expecting growth. Upcoming earnings with expected growth may noticeably affect financial performance and investor sentiment.
27 Apr
Stevanato Group S.p.A. (STVN) stock declined in Q1 due to weaker-than-expected performance in core operations and market challenges. Q1 decline affects key financial metrics and investor sentiment with moderately noticeable but limited long-term impact.
25 Apr
Stevanato Group (STVN) investment story resets amid surging demand for GLP-1 drugs and biologics, positioning the company as a key supplier of specialized glass packaging and drug delivery systems for these high-growth markets. GLP-1 and biologics market expansion drives major demand for STVN's core products, potentially transforming revenue trajectory and investor outlook.
1 Apr
Stevanato Group (STVN) core business improved despite a 22% Q4 pullback. Q4 revenue pullback is countered by core business gains, yielding moderate financial and market effects.
4 Mar
Stevanato Group S.p.A. (STVN) reported strong revenue growth in Q4 2025 earnings call highlights. Strong revenue growth in Q4 2025 earnings highlights major positive shift in financial performance and investor sentiment.
Stevanato Group reported Q4 earnings call highlights, featuring strong revenue growth, improved margins, positive full-year guidance, strategic expansions in biopharma glass and assembly solutions, and optimistic outlook amid rising demand for drug delivery systems. Q4 earnings highlights detail robust financial results and upward guidance, signaling major positive shifts in revenue trajectory and market positioning.
Stevanato Group S.p.A. released Q4 2025 earnings call summary highlighting financial results, operational updates, and forward guidance. Q4 earnings call details financial performance and strategic outlook, significantly influencing investor sentiment and stock trajectory.
Stevanato Group (STVN) surpassed Q4 earnings and revenue estimates. Surpassing Q4 earnings and revenue estimates boosts investor sentiment and signals strong financial performance.
Stevanato Group S.p.A. (STVN) released Q4 earnings snapshot highlighting key financial metrics for the quarter. Q4 earnings snapshots reveal critical financial results that significantly influence stock price and future market performance.
Stevanato Group achieved 7% revenue growth (9% at constant currency) for fiscal year 2025, with record revenue from high-value solutions and expanded margins. Strong revenue growth, record high-value solutions revenue, and margin expansion indicate significant positive impact on financial performance and investor sentiment.
19 Feb
Stevanato Group S.p.A. (STVN) underperformed in Q4 due to adverse factors hurting its financial results and operations. Q4 disappointments are poised to moderately affect STVN's financial performance and investor sentiment without fundamentally altering long-term trajectory.
29 Jan
Stevanato Group S.p.A. has experienced a decline in share price, prompting a reevaluation of its valuation. Analysts are assessing the company's fundamentals and market position amidst recent market fluctuations. The report highlights potential risks and opportunities that could influence future performance, including demand for its products and competitive pressures. Investors are urged to consider these factors when evaluating the stock's potential recovery and growth trajectory. Moderate influence on financial performance and market sentiment is expected due to recent share price weakness and market conditions.
26 Jan
Stevanato Group S.p.A. (STVN) and MDGL are compared in terms of value stock potential. Analysts evaluate financial metrics, growth prospects, and market positioning to determine which stock offers better value for investors. The analysis includes a review of earnings reports, market trends, and competitive advantages, ultimately guiding investors in making informed decisions about their portfolios. The comparison of financial metrics and growth prospects indicates a moderately noticeable influence on investor sentiment and market performance.